Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System

Exclusion Criteria

• •Expected survival period \<12 months;
• •Pregnant women or those unable to take effective contraceptive measures during the trial;
• •Aneurysms present close to the target lesion;
• •Acute or subacute thrombosis within the target vessel;
• •Previously unobstructed internal iliac artery being blocked (diameter stenosis \<70%) by the stented region;
• •Total occlusive lesions, with the guidewire being unable to return the true lumen in the iliac artery;
• •Severe calcification at the target lesion, with the catheter being unable to pass;
• •Allergic to cobalt-chromium alloy (L605), ePFTE coating material, carbon coating, contrast agent, antiplatelet agents, anticoagulant drugs or presenting with contraindications;
• •Total occlusion of the superficial femoral artery and deep femoral artery, with there being no outflow tract;
• •Suffering from extensive diffuse disease at the distal end, resulting in poor blood flow in the outflow tract following stent placement;
• •A history of coagulation disorders;
• •The subject's mental state making it impossible for them to comprehend the nature, extent and possible consequences of the trial, or having a language barrier making it difficult for the subject to give their informed consent;
• •Poor cooperation or potentially poor compliance with the protocol which may cause deviations during the trial.